Skip to main content

Table 1 Summary of baseline characteristics and demographics

From: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

 

Cross-sectional phase

Longitudinal phase

Empty Spiromax followed by empty Turbuhaler

(N = 243a)

Empty Turbuhaler followed by empty Spiromax

(N = 242a)

P-value

BF Spiromax (N = 197a)

BF Turbuhaler (N = 197a)

P-value

Age, years, mean (SD)

54.4 (13.8)

53.1 (14.2)

0.309b

53.3 (14.3)

53.1 (14.1)

0.758b

Height, cm, mean (SD)

167.5 (9.1)

169.3 (9.4)

0.022b

168.1 (8.9)

168.8 (9.5)

0.348b

Sex, male, n (%)

91 (37.4)

108 (44.6)

0.108c

81 (41.1)

82 (41.6)

0.919c

FEV1, mean (SD)

2.5 (0.8)

2.6 (0.8)

0.238b

2.5 (0.8)

2.6 (0.9)

0.305b

ACQ-7, mean (SD)

1.4 (0.9)

1.6 (0.9)

0.043b

1.6 (1.0)

1.6 (0.9)

0.257b

Eosinophil levels, mean cells/nL (SD)

0.3 (0.3)

0.3 (0.3)

0.279b

0.3 (0.2)

0.3 (0.2)

0.595b

Medications, n (%)

 Prior medication

199 (81.9)

195 (80.6)

0.711c

179 (90.9)

184 (93.4)

0.350c

 Concomitant medication

240 (98.8)

240 (99.2)

0.656c

194 (98.5)

196 (99.5)

0.315c

  1. ACQ-7 7-item asthma control questionnaire, BF budesonide formoterol, FEV1 forced expiratory volume in 1 second, SD standard deviation
  2. aIntent-to-treat population
  3. bMann-Whitney U Test
  4. cChi-Squared Test